Q1 EPS Estimate for Precision BioSciences Raised by Analyst

Precision BioSciences, Inc. (NASDAQ:DTIL) – Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Precision BioSciences in a research note issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.27) per share for the quarter, up from their previous forecast of ($0.82). The consensus estimate for Precision BioSciences’ current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Precision BioSciences’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($1.43) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($2.21) EPS.

DTIL has been the subject of several other reports. Jefferies Financial Group restated a “buy” rating and issued a $19.00 price objective on shares of Precision BioSciences in a report on Friday, March 13th. Wall Street Zen raised shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Precision BioSciences presently has an average rating of “Hold” and an average target price of $39.50.

Precision BioSciences Price Performance

Shares of DTIL stock opened at $6.50 on Monday. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $8.82. The company has a current ratio of 13.32, a quick ratio of 13.32 and a debt-to-equity ratio of 0.24. The stock has a fifty day simple moving average of $4.44 and a two-hundred day simple moving average of $5.05. The stock has a market capitalization of $160.62 million, a price-to-earnings ratio of -1.27 and a beta of 1.28.

Insider Buying and Selling

In other Precision BioSciences news, CFO John Alexander Kelly sold 8,149 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total value of $31,292.16. Following the completion of the transaction, the chief financial officer directly owned 125,883 shares in the company, valued at approximately $483,390.72. The trade was a 6.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Michael Amoroso sold 20,559 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $78,946.56. Following the completion of the transaction, the chief executive officer owned 243,392 shares of the company’s stock, valued at $934,625.28. This represents a 7.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,845 shares of company stock worth $376,677 in the last three months. 4.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DTIL. HBK Sorce Advisory LLC bought a new position in shares of Precision BioSciences during the 4th quarter worth approximately $38,000. Engineers Gate Manager LP acquired a new stake in Precision BioSciences in the fourth quarter valued at approximately $43,000. Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences in the fourth quarter worth $52,000. Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences in the third quarter worth $72,000. Finally, Miller Financial Services LLC increased its position in shares of Precision BioSciences by 50.0% during the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after purchasing an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.